Natural Killer T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Natural Killer T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL [Phase 2]
Phase 2 trial evaluating PD-1 antibody-based therapy with concurrent radiation therapy for early-stage natural killer/T-cell lymphoma; curre…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) [Phase 1]
Electra Therapeutics is conducting a Phase 1 trial of ELA026 in relapsed/refractory T-cell and NK/T-cell malignancies, and the study is curr…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL
A Sun Yat-sen University-led clinical trial is evaluating a multi-modal fusion model and deep learning approach to predict treatment respons…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma [Phase 2]
This clinical trial assesses maintenance therapy with selinexor plus azacitidine after allogeneic stem cell transplantation in patients with…
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL [Phase 1, Phase 2]
Phase Ib/II clinical study evaluating tislelizumab combined with golidocitinib and selinexor for relapsed/refractory natural killer/T-cell l…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-04-30Clinical Trial Update: Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies [Phase 1]
A Phase 1 clinical trial (NCT06699771) is evaluating the safety, tolerability, and preliminary efficacy of GCC2005. The trial focuses on pat…
-
CLINICAL_TRIALS research · 2025-03-07Clinical Trial Update: The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
This clinical trial update describes a study evaluating PET imaging targeting Granzyme B as a biomarker to predict efficacy and prognosis in…
-
CLINICAL_TRIALS research · 2024-12-24Clinical Trial Update: The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study
This clinical study assesses whether artificial intelligence-enhanced 18F-FDG PET/CT can aid differential diagnosis, predict treatment effic…
-
CLINICAL_TRIALS research · 2024-12-13Clinical Trial Update: RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies [Phase 1]
Phase 1 clinical trial update for RD13-02 cell injection in patients with relapsed or refractory CD7-positive natural killer/T-cell lymphoma…